Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Halford

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 8, 2005
Refining molecular analysis in the pathways of colorectal carcinogenesisAndrew Rowan, Sarah Halford, Michelle Gaasenbeek, et al.
British Journal of Cancer|February 21, 2020
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
British Journal of Cancer|March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.
British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.
Neuro-Oncology|April 30, 2020
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trialCatherine Hanna, Kathreena M Kurian, Karin Williams, et al.
Oncogene|April 11, 2003
Genome-wide allelotyping of 104 Finnish colorectal cancers reveals an excess of allelic imbalance in chromosome 20q in familial casesPäivi Laiho, Tuija Hienonen, Auli Karhu, et al.
British Journal of Cancer|February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinomaNatalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2016
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical OutcomesKaty J McCann, Ann Mander, Angelica Cazaly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced CancerSarah Halford, Gareth J Veal, Stephen R Wedge, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 8, 2005
Refining molecular analysis in the pathways of colorectal carcinogenesisAndrew Rowan, Sarah Halford, Michelle Gaasenbeek, et al.
British Journal of Cancer|February 21, 2020
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
British Journal of Cancer|March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerYvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.
British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.
Neuro-Oncology|April 30, 2020
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trialCatherine Hanna, Kathreena M Kurian, Karin Williams, et al.
Oncogene|April 11, 2003
Genome-wide allelotyping of 104 Finnish colorectal cancers reveals an excess of allelic imbalance in chromosome 20q in familial casesPäivi Laiho, Tuija Hienonen, Auli Karhu, et al.
British Journal of Cancer|February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinomaNatalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2016
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical OutcomesKaty J McCann, Ann Mander, Angelica Cazaly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced CancerSarah Halford, Gareth J Veal, Stephen R Wedge, et al.
Pageof 3